Corcept Therapeutics Inc (CORT) Institutional Investor Snapshot (430 Funds, Q2 2026)

CORT ranks #1422 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

CORT is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.6% of that fund's own 13F portfolio.

CORT is a top-conviction position for Ingalls & Snyder LLC — at 18.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CORT belongs to BlackRock, Inc., but the position matters far more to Ingalls & Snyder LLC, who has 18.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Cache Advisors, LLC has added to its CORT position for two straight quarters, increasing it by $561.9K to reach $864.2K today.

CORT is down 2.8% today, but institutions show net buying of $1.1B this quarter — a divergence between today's price move and the underlying institutional flow.

CORT posted net income of $55.2M over the trailing twelve months, and currently trades at a P/E of 239.5.

• Profitable — net income of $55.2M over the trailing twelve months
• Revenue grew 16.0% year over year
• Net income declined year over year, from $133.7M to $55.2M
• Generated $142.0M in positive operating cash flow
• Current ratio of 2.92x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.29x equity — within a conventional range